contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


all-patients-in-nanexa-phase-1-study-of-nex-22-dosed-according-to-plan

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Nanexa is a drug delivery company with a proprietary platform that is used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The PharmaShell process is based on ALD (Atomic Layer Deposition) technology, which encloses pharmaceutical particles with a thin shell and creates opportunities for pharmaceutical companies to develop new products. Nanexa has cooperation with several pharmaceutical companies, mainly around the Nordic market.

Nanexa

Nanexa AB today announces that dosing of the last patient has been completed in the Phase 1 study of the long-acting depot formulation of the GLP-1 analog liraglutide PharmaShell®.The dosing...

<div class="mfn-preamble"><p><strong>Nanexa AB today announces that dosing of the last patient has been completed in the Phase 1 study of the long-acting depot formulation of the GLP-1 analog liraglutide PharmaShell®.</strong></p></div><div class="mfn-body"><p>The dosing of NEX-22 in patients with Type 2 Diabetes was completed by end of September at the clinical site in Germany in the third and last dose group. Data from the two first dose groups of the PharmaShell formulation liraglutide shows a prolonged release with a controlled initial release of liraglutide into the bloodstream. The low initial release is positive and may help mitigate common gastrointestinal side effects like nausea associated with starting GLP-1 treatment.</p><p>“Our interim data from the study strengthens our position in business development discussions”, says David Westberg, CEO of Nanexa. “We look forward to presenting the complete Phase 1 study results of NEX-22, that we consider being a unique long-acting GLP-1 formulation with great market potential”.</p><p>Clinicaltrials.gov NCT06439056</p></div><div class="mfn-footer mfn-contacts mfn-2376405b3437"><p><strong class="mfn-heading-1">For additional information, please contact:</strong></p><hr><p>David Westberg – CEO, Nanexa AB (publ)&nbsp;<br>Phone: +46 70 942 83 03<br>Email:&nbsp;<a rel="noopener" href="mailto:david.westberg@nanexa.se">david.westberg@nanexa.se</a><br><a rel="noopener" href="http://www.nanexa.com/">www.nanexa.com</a></p><p>The company’s Certified Adviser is Carnegie Investment Bank AB (publ).</p></div><div class="mfn-footer mfn-about mfn-c9ba281e2dde"><p><strong class="mfn-heading-1">About Nanexa AB (publ)</strong></p><hr><p>Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.</p><p>Nanexa’s share is listed&nbsp;on Nasdaq First North Growth Market in Stockholm (NANEXA).</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/31dd297c-b9fd-40a8-b0ae-50b6e3c8b185/all-patients-in-nanexa-phase-1-study-of-nex-22-dosed-according-to-plan.pdf" class="mfn-generated mfn-primary">All patients in Nanexa Phase 1 study of NEX-22 dosed according to plan</a></p></div>

Stay up to date with our newsletter